Видео с ютуба Speaker: Tycel Phillips

Retrospective study on outcomes and safety of covalent BTK inhibitors for the treatment of MCL

The development of predictive biomarkers for bispecifics, CAR-T, or ADCs in lymphoma

Long-term disease control associated with epcoritamab and CAR T-cell therapy in LBCL

The evolving paradigm of frontline DLBCL treatment: strategies being explored in trial

Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations

Areas of unmet need for DLBCL: primary refractory disease and double-hit lymphoma

Estimating long-term outcomes in patients with cHL using an oncology simulation model

The efficacy of glofitamab in patients with heavily pre-treated R/R MCL

Unmet needs and current perspectives in high-risk MCL

Safety and efficacy of plamotamab in the treatment of non-Hodgkin lymphoma subtypes

Phase I study of plamotamab in R/R NHL

Interim analysis of a Phase II study of the GLOVe regimen in untreated, high-risk MCL

CAR T-cells and bispecific antibodies in lymphoma: current perspectives and future considerations

Glofitamab induces high response rates in high-risk MCL: subgroup analysis from a Phase I/II study

Insights into an oncology simulation model being used to evaluate treatment regimens in HL

Evaluating whether prior bendamustine exposure impacts the efficacy of epcoritamab in DLBCL

Limitations of current risk stratification systems in FL & treatment options for high-risk patients

The role of selinexor in DLBCL and the challenges of implementing this agent in patients

Updates on the use of CAR-T therapy in MCL

Ongoing clinical trials to look out for in lymphoma